Get Sample Pages - Next Generation Immunotherapy Market Share, Size

Global Next Generation Immunotherapy Market Research Report: Forecast (2024-2029)

By Type (Vaccines, Immune Checkpoint Modulators, CAR-T Cell Therapy, Tumor-Infiltrating Lymphocytes [TILs] Therapy, Bispecific Antibodies, Oncolytic Virus Therapy, Others), By Rout......e of Administration (Intravenous, Intratumoral, Subcutaneous, Oral), By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Research Centers), By Region (North America,, South America,, Europe,, Middle East & Africa,, Asia-Pacific), By Company (Bristol Myers Squibb, Regeneron Pharmaceuticals, MacroGenics, AbbVie Inc., Pfizer Inc., Novartis, Merck & Co., Inc., AstraZeneca, Incyte Corporation, Eli Lilly and Company, Johnson and Johnson, Others,) Read more

Healthcare
Oct 2023
Pages 198
Report Format: PDF, Excel, PPT

Market Definition

The Next Generation Immunotherapy encompasses innovative therapies that harness the immune system to target and eradicate diseases like cancer, autoimmune disorders, infectious diseases, and others. It involves advanced technologies like genetically engineered cells, immune checkpoint inhibitors, and monoclonal antibodies. These therapies aim to improve treatment efficacy, minimize side effects, and enhance patient outcomes.

Market Insights & Analysis: Global Next Generation Immunotherapy Market (2024-29):

Global Next Generation Immunotherapy Market is projected to grow at a CAGR of around 7.5% during the forecast period, i.e., 2024-29. Some of the key factors propelling the market growth included the rising burden of chronic diseases, increasing research in the area of next-generation drugs, and an increased focus on targeted therapies for certain diseases. Also, the factor majorly affecting the Global Next Generation Immunotherapy Market was the rising prevalence of chronic diseases like asthma, allergic conditions, cancer, and multiple sclerosis.

Report Coverage	Details
Study Period	Historical Data: 2019-22
	Base Year: 2023
	Forecast Period: 2024-29
CAGR (2024-2029)	7.5%
Regions Covered	North America: US, Canada, Mexico
	Europe: Germany, The UK, France, Spain, Italy, Rest of Europe
	Asia-Pacific: China, India, Japan, South Korea, Singapore, Australia, Rest of Asia-Pacific
	South America: Brazil, Rest of South America
	Middle East & Africa: GCC, South Africa, Rest of MEA
Key Companies Profiled	Bristol Myers Squibb, Regeneron Pharmaceuticals, MacroGenics, AbbVie Inc., Pfizer Inc., Novartis, Merck & Co., Inc., AstraZeneca, Incyte Corporation, Eli Lilly and Company, Johnson and Johnson, Others
Unit Denominations	USD Million/Billion

For instance, in 2020, as per the World Health Organization, cancer accounted for around 9.9 million deaths and remains the second leading cause of death worldwide. The burden is projected to increase in the future because risk factors including smoking, unhealthy eating habits, and not exercising are becoming more prevalent in economically developing countries. With a growing number of chronic diseases, demand for novel drugs would improve, further contributing to market growth.

Furthermore, the key activities undertaken by the various companies have also been supporting the market growth. Companies involved in offering next-generation immunotherapy have been investing heavily in clinical trials and research to develop and validate innovative immunotherapies. These trials have been crucial for demonstrating the safety and efficacy of new treatments, gaining regulatory approvals, and expanding the range of conditions and patient populations that can be catered to with advanced immunotherapy approaches.

For instance, in 2022, Human Immunology Biosciences Inc. announced that it had raised USD120 million to develop targeted treatments for autoimmune and allergic diseases. The company developed two drug candidates, called felzartamab and HIB210, that were licensed by the German biotechnology company MorphoSys. Both are in clinical trials, with the former in Phase 2 testing for two rare kidney diseases and the latter in Phase 1.

Hence, owing to the increasing focus of companies such as Human Immunology Biosciences Inc, Merck & Co., Inc., Bristol Myers Squibb (BMS), etc. on developing such novel drugs, it is expected that the market is likely to witness strong growth. It would be attributed to the increased efficacy of the novel drugs and increased patient pool which would be prescribed with next-generation immunotherapies in the coming years.

Global Next Generation Immunotherapy Market Driver:

Growing Adoption of Chimeric Antigen Receptor (CAR) T-cell Therapy – In recent years, there has been a high demand for chimeric antigen receptor (CAR) T-cell therapy, which has been majorly driven by the rising prevalence of relapsed B-cell acute lymphoblastic leukemia (ALL) and specific non-Hodgkin lymphomas. For instance,

In 2020, according to the GLOBOCON, non-Hodgkin lymphomas (NHL) have been ranked as one of the most common cancers and had an estimated 544,000 new cancer cases and 260,000 cancer deaths in 2020.

Global Next Generation Immunotherapy Market Research Report (2024-2029) - Table of Contents

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
Global Next Generation Immunotherapy Market Patent Analysis, 2019-2023
Global Next Generation Immunotherapy Market Recent Approvals, 2019-2023
Global Next Generation Immunotherapy Market Clinical Trial Analysis, 2019-2023
Global Immunotherapy Market Evolution, 2000-2023
Global Next Generation Immunotherapy Market Trends & Insights
Global Next Generation Immunotherapy Market Dynamics
1. Drivers
2. Challenges
Global Next Generation Immunotherapy Market Hotspot & Opportunities
Global Next Generation Immunotherapy Market Policies, Regulations, Product Standards
Global Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type
    1. Vaccines- Market Size & Forecast 2019-2029F, USD Million
      1. mRNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
      2. DNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
      3. Protein Vaccines- Market Size & Forecast 2019-2029, USD Million
      4. Others (Viral Vector Vaccines, Nanoparticle Vaccines, etc.)- Market Size & Forecast 2019-2029, USD Million
    2. Immune Checkpoint Modulators- Market Size & Forecast 2019-2029F, USD Million
    3. CAR-T Cell Therapy- Market Size & Forecast 2019-2029F, USD Million
    4. Tumor-Infiltrating Lymphocytes (TILs) Therapy- Market Size & Forecast 2019-2029F, USD Million
    5. Bispecific Antibodies- Market Size & Forecast 2019-2029F, USD Million
    6. Oncolytic Virus Therapy- Market Size & Forecast 2019-2029F, USD Million
    7. Others (Antibody-drug Conjugates, ACE Inhibitors, etc.)- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration
    1. Intravenous- Market Size & Forecast 2019-2029F, USD Million
    2. Intratumoral- Market Size & Forecast 2019-2029F, USD Million
    3. Subcutaneous- Market Size & Forecast 2019-2029F, USD Million
    4. Oral- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area
    1. Oncology- Market Size & Forecast 2019-2029F, USD Million
    2. Autoimmune Diseases- Market Size & Forecast 2019-2029F, USD Million
    3. Infectious Diseases- Market Size & Forecast 2019-2029F, USD Million
    4. Inflammatory Diseases- Market Size & Forecast 2019-2029F, USD Million
    5. Others (Neurological Disorders, B-cell Malignancies, etc.) - Market Size & Forecast 2019-2029F, USD Million
  4. By End User
    1. Hospitals- Market Size & Forecast 2019-2029F, USD Million
    2. Specialty Clinics- Market Size & Forecast 2019-2029F, USD Million
    3. Ambulatory Surgical Centres- Market Size & Forecast 2019-2029F, USD Million
    4. Cancer Research Centres- Market Size & Forecast 2019-2029F, USD Million
  5. By Region
    1. North America
    2. South America
    3. Europe
    4. Middle East & Africa
    5. Asia-Pacific
  6. By Competition
    1. Market Share of Top Companies
    2. Competition Characteristics
North America Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
  4. By End User- Market Size & Forecast 2019-2029F, USD Million
  5. By Country
    1. The US
    2. Canada
    3. Mexico
3. The US Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
4. Canada Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
5. Mexico Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
South America Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
  4. By End User- Market Size & Forecast 2019-2029F, USD Million
  5. By Country
    1. Brazil
    2. Rest of South America
3. Brazil Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
Europe Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
  4. By End User- Market Size & Forecast 2019-2029F, USD Million
  5. By Country
    1. Germany
    2. The UK
    3. France
    4. Italy
    5. Spain
    6. Rest of Europe
3. Germany Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
4. The UK Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
5. France Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
6. Italy Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
7. Spain Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
Middle East & Africa Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
  4. By End User- Market Size & Forecast 2019-2029F, USD Million
  5. By Country
    1. GCC
    2. South Africa
    3. Rest of Middle East & Africa
3. GCC Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
4. South Africa Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
Asia-Pacific Next Generation Immunotherapy Market Outlook, 2019-2029F
1. Market Size & Analysis
  1. By Revenues (USD Million)
2. Market Share & Analysis
  1. By Type- Market Size & Forecast 2019-2029F, USD Million
  2. By Route of Administration- Market Size & Forecast 2019-2029F, USD Million
  3. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
  4. By End User- Market Size & Forecast 2019-2029F, USD Million
  5. By Country
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Singapore
    6. Australia
    7. Rest of Asia-Pacific
3. China Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
4. India Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
5. Japan Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
6. South Korea Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
7. Singapore Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
8. Australia Next Generation Immunotherapy Market Outlook, 2019-2029F
  1. Market Size & Analysis
    1. By Revenues (USD Million)
  2. Market Share & Analysis
    1. By Type- Market Size & Forecast 2019-2029F, USD Million
    2. By Therapeutic Area- Market Size & Forecast 2019-2029F, USD Million
Global Next Generation Immunotherapy Market Key Strategic Imperatives for Success & Growth
Competition Outlook
1. Company Profiles
  1. Bristol Myers Squibb
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  2. Regeneron Pharmaceuticals
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  3. MacroGenics
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  4. AbbVie Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  5. Pfizer Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  6. Novartis
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  7. Merck & Co., Inc.
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  8. AstraZeneca
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  9. Incyte Corporation
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  10. Eli Lilly and Company
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  11. Johnson and Johnson
    1. Business Description
    2. Product Portfolio
    3. Strategic Alliances or Partnerships
    4. Recent Developments
    5. Financial Details
    6. Others
  12. Others
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO GET THE FREE SAMPLE PAGES

Name *

Email ID *

Country *